Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Based on promising progression-free survival (PFS) interim analysis, trial to continue and an optimized number of patients to be randomized in the trial Management to host webcast presentation of
TG4001- Results from the interim analysis of the randomized Phase II trial in HPV-positive anogenital cancers to be released in Q4 2022 TG4050 (myvac platform) - New positive Phase I data presented
Strasbourg, France, and Lund, Sweden, June 28, 2022, 8:00 am CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on th.